NR5A2 and colorectal carcinoma: Although until now, only one clinical trial modulating LRH-1 activity has been carried out (ClinicalTrials.gov Identifier: NCT03481608), it would be intriguing to analyze the effect of LRH-1 agonists administration in IBD and CRC.